• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 3. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An investigation on the interaction modes of a single-strand DNA aptamer and RBP4 protein: a molecular dynamic simulations approach?
  Raheleh Torabi,Hedayatollah Ghourchian,Massoud Amanlou Org. Biomol. Chem., 2016,14, 8141-8153

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Tannins Hydrolyzable tannins
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Introduction to Schisandrin (CAS No. 7432-28-2)

Schisandrin, a naturally occurring lignan derivative, is primarily extracted from the fruits of Schisandra chinensis, a plant widely recognized in traditional Chinese medicine for its multifaceted health benefits. With the CAS number 7432-28-2, this compound has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and promising biological activities. The recent advancements in molecular pharmacology have further highlighted the therapeutic potential of Schisandrin, particularly in the areas of neuroprotection, anti-inflammatory responses, and metabolic regulation.

The chemical structure of Schisandrin consists of two coupled naphthalene units linked by a phenolic bridge, which contributes to its remarkable stability and bioavailability. This structural feature has been a focal point in synthetic chemistry, where researchers have been exploring various derivatives to enhance its pharmacological efficacy. The compound's ability to cross the blood-brain barrier has opened new avenues for treating neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Preliminary studies have demonstrated that Schisandrin can modulate neurotransmitter levels and protect neuronal cells from oxidative stress, making it a promising candidate for further clinical development.

In the realm of anti-inflammatory research, Schisandrin has shown significant promise as a natural anti-inflammatory agent. Its mechanism of action involves inhibiting key pro-inflammatory cytokines such as TNF-α and IL-6, which are central mediators in chronic inflammatory diseases. The compound's ability to suppress NF-κB signaling pathways has been particularly noted in preclinical studies, suggesting its potential in managing conditions like rheumatoid arthritis and inflammatory bowel disease. Additionally, Schisandrin's antioxidant properties contribute to its anti-inflammatory effects by neutralizing reactive oxygen species (ROS) that often exacerbate inflammation.

Metabolic disorders, including obesity and type 2 diabetes, have also been areas of interest where Schisandrin demonstrates therapeutic potential. Research indicates that Schisandrin can enhance insulin sensitivity by improving glucose uptake in adipose tissues. Furthermore, it has been observed to modulate lipid metabolism by inhibiting fatty acid synthase (FASN), thereby reducing triglyceride accumulation. These findings have prompted further investigation into Schisandrin as a potential adjunct therapy for metabolic syndrome.

The pharmacokinetic profile of Schisandrin has been extensively studied to optimize its delivery and efficacy. Oral administration has shown moderate bioavailability due to rapid metabolism in the liver. However, recent developments in nanotechnology have provided innovative solutions to enhance its absorption and distribution. Encapsulation of Schisandrin within lipid nanoparticles has demonstrated improved bioavailability and targeted delivery to affected tissues, thereby increasing therapeutic efficacy.

Recent clinical trials have begun to explore the safety and efficacy of Schisandrin in human populations. Phase II trials focusing on neurodegenerative diseases have reported encouraging results regarding cognitive improvement and reduced oxidative stress markers. Similarly, pilot studies in patients with metabolic disorders have shown positive trends in glycemic control and weight management. These preliminary findings underscore the need for larger-scale clinical investigations to fully elucidate the therapeutic benefits of Schisandrin.

The future direction of Schisandrin research is likely to focus on identifying specific molecular targets and optimizing formulations for targeted drug delivery. Advances in computational chemistry and artificial intelligence are expected to accelerate the discovery of novel derivatives with enhanced pharmacological properties. Collaborative efforts between academia and industry will be crucial in translating preclinical findings into clinical applications, ensuring that Schisandrin reaches its full potential as a therapeutic agent.

In conclusion, Schisandrin (CAS No. 7432-28-2) represents a compelling natural product with diverse therapeutic applications ranging from neuroprotection to metabolic regulation. Its unique chemical structure, coupled with promising biological activities, positions it as a valuable candidate for further research and development. As scientific understanding continues to evolve, Schisandrin is poised to play an increasingly significant role in modern medicine.

• 62956-48-3(Gomisin G)
• 58-95-7(a-Tocopherol Acetate)
• 59-02-9(Vitamin E)
• 61281-37-6(Schisandrin B)
• 66056-20-0(Gomisin H)
• 475-67-2(Isocorydine)
• 54-28-4(γ-Tocopherol)
• 58546-54-6(Schisandrol B)
• 72-33-3(Mestranol)
• 476-70-0(Boldine)